publication venue for

• Early-Phase Trial of IAP Antagonist Tolinapant and Definitive Radiation in Cisplatin-Ineligible Patients with Advanced Head and Neck Cancer 2025
• Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis 2024
• Preliminary results from an early-phase, open-label study of tolinapant and radiation in cisplatin-ineligible patients with previously untreated, locally advanced head and neck cancer 2023
• Antagonist of cIAP1/2 and XIAP induces immunogenic cell death and alters antigen-processing machinery in preclinical head and neck cancer models 2020
• Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models 2020
• Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells 2020
• Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV^- and HPV⁺ Head and Neck Cancers to TNFα, TRAIL, and Radiation Therapy 2019